Trial Profile
A multicentre, retrospective study to evaluate the efficacy of sorafenib versus sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Apr 2016 New trial record